Combined organ and hematopoietic cells for transplantation tolerance of grafts

Patent metadata

Field	Value
Publication number	US-11426429-B2
Application number	US-201916447691-A
Country	US
Kind code	B2
Filing date	Jun 20, 2019
Priority date	Feb 26, 2013
Publication date	Aug 30, 2022
Grant date	Aug 30, 2022

Abstract

Methods and compositions are provided for combined transplantation of a solid organ and hematopoietic cells to a recipient, where tolerance to the graft is established through development of a persistent mixed chimerism. An individual with persistent mixed chimerism, usually for a period of at least six months, is able to withdraw from the use of immunosuppressive drugs after a period of time sufficient to establish tolerance.

First claim

What is claimed is:

1. A method for manufacturing a cellular product, the method comprising:
receiving an apheresis product from a donor comprising hematopoietic stem cells comprising CD34+ cells and CD3+ cells;
removing blood cells and platelets from the apheresis product;
processing the apheresis product to produce a cellular product comprising at least 0.5×10 6 CD34+ cells/kg recipient and at least 1×10 6 CD3+ cells/kg recipient and a cell type that facilitates engraftment of the hematopoietic stem cells in a bone marrow of a recipient of a solid organ transplant;
analyzing the cellular product for one or more quality criteria; and
cryopreserving the cellular product.

2. The method of claim 1 , further comprising shipping the cryopreserved cellular product to a location where the solid organ transplant is occurring.

3. The method of claim 1 , wherein the one or more quality criteria are at least one quality criteria selected from the group consisting of cell count, viability, sterility, and a combination thereof.

4. The method of claim 3 , wherein the one or more quality criteria is cell count of the hematopoietic stem cells, and an amount of the hematopoietic stem cells in the cellular composition is adjusted based on results of the cell count.

5. The method of claim 1 , wherein the apheresis product is from a donor that is HLA matched to the recipient.

6. The method of claim 1 , wherein the apheresis product is from a donor that is HLA mis-matched to the recipient.

7. The method of claim 1 , wherein the cellular product is formulated for infusion into the recipient.

8. The method of claim 1 , wherein the cell type that facilitates engraftment of the hematopoietic stem cells in the bone marrow of the recipient is a complementary cell type.

9. The method of claim 8 , wherein the complementary cell type is one or more type of endothelial cell.

10. The method of claim 1 , wherein receiving the apheresis product from the donor comprises sampling the apheresis product during collection.

11. The method of claim 10 , wherein sampling comprises measuring the white blood cell count and/or platelet count during collection.

12. The method of claim 11 , further comprising adjusting the rate of collection based on the measured white blood cell count and/or platelet count during collection.

13. The method of claim 1 , wherein the cellular product is cryopreserved using a cryopreservation medium containing dimethylsulfoxide (DMSO).

Assignees

• Univ Leland Stanford Junior

Inventors

• Strober Samuel
• Lowsky Robert

Classifications

• A61K35/14 Primary

  Blood; Artificial blood (perfluorocarbons A61K31/02; umbilical cord blood A61K35/51; haemoglobin A61K38/42) · CPC title

• A61K2039/57

  characterised by the type of response, e.g. Th1, Th2 · CPC title

• A61K38/193

  Colony stimulating factors [CSF] · CPC title

• A61N5/10

  X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy (A61N5/01 takes precedence) · CPC title

• A61K35/28

  Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells · CPC title